trans-4-(3,4-dichlorophenyl)-1-(phenylmethyl)-3-pyrrolidinecarboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: trans-4-(3,4-dichlorophenyl)-1-(phenylmethyl)-3-pyrrolidinecarboxylic acid
• 英文别名: (3RS,4SR)-1-benzyl-4-(3,4-dichlorophenyl)pyrrolidine-3-carboxylic acid；(3R,4S)-1-benzyl-4-(3,4-dichlorophenyl)pyrrolidine-3-carboxylic acid
• 化学式: C₁₈H₁₇Cl₂NO₂
• 分子量: 350.244
• InChiKey: CPNNNTHMABGFLD-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  trans-4-(3,4-dichlorophenyl)-1-(phenylmethyl)-3-pyrrolidinecarboxylic acid 在 copper(l) iodide 、 叠氮磷酸二苯酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 26.67h， 生成 1-<<<2-(trimethylsilyl)ethoxy>carbonyl>oxy>-1,1-dimethylethyl trans-<4-(3,4-dichlorophenyl)-3-pyrrolidinyl>carbamate
  参考文献：
  名称：

  Synthesis and antimicrobial evaluation of a series of 7-[3-amino (or aminomethyl)-4-aryl (or cyclopropyl)-1-pyrrolidinyl]-4-quinolone and -1,8-naphthyridone-3-carboxylic acids

  摘要：

  A series of 6-fluoroquinolone- and 6-fluoro-1,8-naphthyridone-3-carboxylic acids possessing a [3-amino (or aminomethyl)-4-aryl (or cyclopropyl)-1-pyrrolidinyl] group at C-7 were synthesized and evaluated for their antimicrobial activity. The effect of the relative stereochemistry of the pyrrolidinyl substituents, as well as the presence of different functional groups on the 4-aryl (or cyclopropyl) moiety, was investigated in conjunction with their attachment to several quinolone or naphthyridone nuclei. In general, the incorporation of substituents on the aryl (or cyclopropyl) ring decreased in vitro and in vivo activity, regardless of the nature and relative position of the substituent. Bulky, lipophilic groups and substitution at the 2- and 3-position of the aromatic ring were particularly deleterious. Within a limited subset of derivatives, cis substitution of the pyrrolidine ring was less favorable than trans substitution. The majority of these effects were more apparent against the Enterobacteriaceae than against any other Gram-negative or Gram-positive organism and could be associated with negative interactions related to permeability or transport factors.

  DOI：

  10.1021/jm00078a002
• 作为产物：
  描述：

  (E)-3-(3,4-二氯苯基)丙烯酸 、 N-(甲氧甲基)-N-(三甲基硅甲基)苄胺 在 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 以94%的产率得到trans-4-(3,4-dichlorophenyl)-1-(phenylmethyl)-3-pyrrolidinecarboxylic acid
  参考文献：
  名称：

  PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS

  摘要：

  该发明涉及一种化合物，其化学式为I，其中Ar1、Ar2、R1、R2、R3、R4、n、o、p和q如本文所定义，并且涉及其药用活性盐，包括化合物(I)的所有立体异构形式、单个对映体异构体和对映体，以及其外消旋和非外消旋混合物。这些化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）。

  公开号：

  US20090042896A1

文献信息

• Nitrogen-containing heterocyclic compound and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090156572A1

  公开（公告）日：2009-06-18

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

  本发明涉及一种由下式表示的化合物：其中环A是含氮杂环，可选择地进一步具有取代基，环B是芳香环，可选择地具有取代基，环C是环状基团，可选择地具有取代基，R1是氢原子，一个碳氢基团，可选择地具有取代基，酰基，一个杂环基团，可选择地具有取代基或一个氨基团，可选择地具有取代基，R2是可选择卤代的C1-6烷基基团，m和n分别是0到5的整数，m+n是2到5的整数，是单键或双键，或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用，可用作预防或治疗多种疾病的药物，如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。
• PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS
  申请人：Jablonski Philippe

  公开号：US20090042896A1

  公开（公告）日：2009-02-12

  The invention relates to a compound of formula I wherein Ar 1 , Ar 2 , R 1 , R 2 , R 3 , R 4 , n, o, p, and q are as defined herein and to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  该发明涉及一种化合物，其化学式为I，其中Ar1、Ar2、R1、R2、R3、R4、n、o、p和q如本文所定义，并且涉及其药用活性盐，包括化合物(I)的所有立体异构形式、单个对映体异构体和对映体，以及其外消旋和非外消旋混合物。这些化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2336105B9

  公开（公告）日：2014-09-17
• PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2398768B1

  公开（公告）日：2016-08-24
• US8470816B2
  申请人：——

  公开号：US8470816B2

  公开（公告）日：2013-06-25